| Trial ID: | L1392 |
| Source ID: | NCT00854139
|
| Associated Drug: |
Cyclophosphamide, Anti-Thymocyte Globulin
|
| Title: |
Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Multiple Myeloma|End Stage Renal Disease
|
| Interventions: |
DRUG: Cyclophosphamide, anti-thymocyte globulin|PROCEDURE: Kidney transplant|RADIATION: Thymic irradiation|PROCEDURE: Bone marrow transplant from a related donor
|
| Outcome Measures: |
Primary: Remission status of multiple myeloma, 3 years|Renal allograft acceptance and ability to discontinue immunosuppressive therapy, 3 years | Secondary: Graft versus host disease (GVHD), 3 years|Opportunistic infections, 3 years|T cell recovery and immune reconstitution, 3 years
|
| Sponsor/Collaborators: |
Sponsor: Massachusetts General Hospital
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
10
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2001-08
|
| Completion Date: |
2014-07
|
| Results First Posted: |
|
| Last Update Posted: |
2020-03-04
|
| Locations: |
Massachusetts General Hospital, Boston, Massachusetts, 02114, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT00854139
|
